California-based Avanir Pharmaceuticals filed a WARN notice in late October detailing 109 layoffs in California at its headquarters in Aliso Viejo, on the south side of Los Angeles. Avanir did not respond to multiple queries from Endpoints News.
From sea to shining sea, pharma layoffs are happening in the United States, according to Worker Adjustment and Retraining Notification (WARN) filings.
Avanir Pharmaceuticals, Inc. today announced it has joined California Life Sciences (CLS), the state's most influential and impactful life sciences membership organization, advocating for the sector and its diverse innovation pipeline.Â
ORANGE COUNTY, Calif., June 16, 2020 /PRNewswire/ -- Avanir Pharmaceuticals, Inc. and The UCI Paul Merage School of Business are pleased to announce the appointment of two new executives to the School's Center for Health Care Management and Policy advisory board. Wa'el Hashad, president and CEO of Avanir Pharmaceuticals, and Lisa Locklear, vice president and CFO of Avanir Pharmaceuticals, have joined forces with the school to help advance the mission of preparing business leaders for a digitally driven world.
Avanir Pharmaceuticals, fresh off a $116 million kickbacks settlement with the feds and tarnished by unflattering news reports, now plans to lay off 140 California employees, a public filing shows.
Otsuka and its subsidiary Avanir have decided to press on with an investigational drug for the treatment of agitation in Alzheimer’s patients, despite announcing a month ago that it didn't show a significant reduction in symptoms.
ALISO VIEJO, Calif., Nov. 12, 2019 /PRNewswire/ -- Avanir Pharmaceuticals, Inc., a pharmaceutical company committed to delivering innovative central nervous system (CNS) solutions to improve the lives of patients and their care communities, announced today that it will continue the clinical development program of AVP-786 (deudextromethorphan hydrobromide [d6-DM]/quinidine sulfate [Q]) for the treatment of agitation in patients with Alzheimer's dementia. The decision is based on insights derived from detailed analysis of data from the first and second phase 3 AVP-786 clinical trials. Preliminary results of the first and second phase 3 clinical trials (15-AVP-786-301 and 15-AVP-786-302) were released March 25 and September 27, 2019, respectively.
Otsuka’s Avanir unit has been dealt yet another setback after its second phase 3 trial of its new drug for agitation in Alzheimer’s disease missed the mark.
Avanir’s no good, awful, simply terrible week came to a disastrous end last Friday as the Otsuka subsidiary was forced to report that its second Phase III trial for a new-and-improved version of its commercial drug had failed in treating Alzheimer’s dementia — likely scuttling any future it may have had in the most difficult of all diseases.
Otsuka Pharmaceutical’s Avanir Pharma has agreed to pay $116 million to settle allegations that it paid doctors kickbacks to boost prescriptions of Neudexta among dementia patients, for whom the drug is not approved. In a national expansion of a volume-based procurement program in China, seven foreign pharmas won contracts at prices that weren't as low as some may have feared. India's securities watchdog slapped a $3 million fine on Aurobindo founder over insider trading amid a Pfizer licensing deal in 2009. And more.